Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

CRAXI, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 39.847
EU - Europa 17.541
AS - Asia 15.814
SA - Sud America 2.394
AF - Africa 459
OC - Oceania 53
Continente sconosciuto - Info sul continente non disponibili 32
Totale 76.140
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 39.368
SG - Singapore 6.083
RU - Federazione Russa 4.632
CN - Cina 4.022
IT - Italia 3.617
FI - Finlandia 2.022
BR - Brasile 1.928
HK - Hong Kong 1.570
DE - Germania 1.386
VN - Vietnam 1.342
UA - Ucraina 1.277
PL - Polonia 986
GB - Regno Unito 842
IE - Irlanda 812
FR - Francia 748
JP - Giappone 526
BD - Bangladesh 507
IN - India 367
SE - Svezia 353
KR - Corea 322
TR - Turchia 236
CA - Canada 220
RO - Romania 187
AR - Argentina 151
NL - Olanda 141
IQ - Iraq 137
MX - Messico 137
AT - Austria 101
ZA - Sudafrica 95
CI - Costa d'Avorio 93
BE - Belgio 89
UZ - Uzbekistan 76
PK - Pakistan 69
ES - Italia 68
EC - Ecuador 64
SA - Arabia Saudita 60
CO - Colombia 58
IR - Iran 54
ID - Indonesia 53
MA - Marocco 53
CL - Cile 51
EG - Egitto 49
VE - Venezuela 49
PH - Filippine 48
KE - Kenya 45
AU - Australia 44
MY - Malesia 44
CH - Svizzera 39
CZ - Repubblica Ceca 37
PY - Paraguay 37
AZ - Azerbaigian 33
NP - Nepal 33
GR - Grecia 31
BG - Bulgaria 30
JM - Giamaica 30
LB - Libano 27
TN - Tunisia 27
JO - Giordania 26
AE - Emirati Arabi Uniti 25
DZ - Algeria 24
LT - Lituania 21
TH - Thailandia 21
DK - Danimarca 20
PE - Perù 20
BO - Bolivia 18
EU - Europa 18
AL - Albania 16
KG - Kirghizistan 16
KZ - Kazakistan 16
OM - Oman 14
SN - Senegal 14
TW - Taiwan 14
UY - Uruguay 14
BY - Bielorussia 13
PA - Panama 13
DO - Repubblica Dominicana 12
IL - Israele 12
GE - Georgia 11
HN - Honduras 11
NI - Nicaragua 11
NG - Nigeria 10
CR - Costa Rica 9
ET - Etiopia 9
GT - Guatemala 9
PS - Palestinian Territory 9
BA - Bosnia-Erzegovina 8
BH - Bahrain 8
MD - Moldavia 8
PT - Portogallo 8
MM - Myanmar 7
RS - Serbia 7
SI - Slovenia 7
SV - El Salvador 7
TT - Trinidad e Tobago 7
AO - Angola 6
BN - Brunei Darussalam 6
GA - Gabon 6
HU - Ungheria 6
LV - Lettonia 6
NZ - Nuova Zelanda 6
Totale 76.035
Salva come PNG Salva come JPEG
Città #
Fairfield 5.452
Ashburn 4.546
Singapore 4.319
Woodbridge 2.682
Chandler 2.170
Seattle 2.155
Wilmington 2.153
Houston 2.123
Cambridge 1.907
San Jose 1.809
Hong Kong 1.501
Ann Arbor 1.348
Zgierz 881
Palermo 828
Dublin 804
Medford 729
Moscow 713
Jacksonville 654
Beijing 596
Altamura 573
Des Moines 553
Council Bluffs 545
Santa Clara 500
Tokyo 495
Nanjing 491
Helsinki 471
Los Angeles 467
Princeton 460
Ho Chi Minh City 457
Frankfurt am Main 428
New York 411
Lawrence 409
Lauterbourg 405
Boardman 347
San Diego 347
Hanoi 327
Dallas 273
Dearborn 223
Tulsa 197
Chicago 196
The Dalles 180
Buffalo 171
Shenyang 166
Hefei 160
Milan 160
São Paulo 159
London 157
Jinan 155
Nanchang 152
Changsha 129
Phoenix 125
Hebei 116
Tianjin 110
Jiaxing 109
Nuremberg 104
Orem 104
Ludwigshafen am Rhein 95
Abidjan 93
Columbus 93
Rome 88
San Paolo di Civitate 88
Istanbul 87
Zhengzhou 85
Seongnam 83
Brussels 82
Izmir 74
Chennai 72
Warsaw 72
Saint Petersburg 70
Amsterdam 68
Guangzhou 67
Ningbo 66
Atlanta 65
Haiphong 58
Munich 57
Paris 55
Rio de Janeiro 55
Falls Church 53
Hangzhou 53
Tashkent 53
Baghdad 52
Da Nang 52
Johannesburg 50
Kumar 50
Brooklyn 49
Mumbai 49
Verona 47
Denver 46
Montreal 45
Redwood City 44
Curitiba 43
Shanghai 43
Nairobi 42
Venice 41
Auburn Hills 40
City of London 40
Ottawa 40
Stockholm 40
Taizhou 40
Vienna 40
Totale 50.827
Salva come PNG Salva come JPEG
Nome #
EASL Clinical Practice Guidelines: management of hepatitis C virus infection 394
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis 393
The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease 337
Alexithymia and personality traits of patients with inflammatory bowel disease 336
A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. 330
Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b 327
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals 325
Hepatitis B virus reactivation and alemtuzumab therapy 312
HCV genotypes in Sicily: is there any evidence of a shift? 310
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030 310
Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. 307
Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. 305
Transmembrane 6 Superfamily Member 2 Gene Variant Disentangles Nonalcoholic Steatohepatitis From Cardiovascular Disease 302
Clinical course and genetic susceptibility of primary biliary cirrhosis: Analysis of a prospective cohort 300
Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease 298
Clinical course and management of acute and chronic viral hepatitis during pregnancy. 298
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 296
The presence of white matter lesions is associated with the fibrosis severity of nonalcoholic fatty liver disease 294
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension 293
HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin 292
Expansion of intestinal CD4+CD25(high) Treg cells in patients with ankylosing spondylitis: a putative role for interleukin-10 in preventing intestinal Th17 response 286
L’insulino-resistenza è il principale fattore indipendente correlato con l’aumentato rischio metabolico nelle donne affette da PCOS 282
Characteristics of liver cirrhosis in Italy: results from a multicenter national study 280
Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. 279
Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 277
Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response 274
Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication. 273
Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 269
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation 267
Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of transcription-mediated amplification assay 263
751 RETINOL-BINDING PROTEIN 4 (RBP4): A NEW MARKER OF G1 HCV-INDUCED STEATOSIS 262
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 262
Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis 259
Clinical implications of the hyperdynamic syndrome in cirrhosis. 257
Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS 256
Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract 255
Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C 254
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. 253
PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 253
The Hepatic Expression of Vitamin D Receptor is Inversely Associated with the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients. 252
Characteristics of HCV positive subjects referring to hospitals in Italy: a multicentre prevalence study on 6,999 cases 249
Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection 248
Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. 247
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. 247
Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study. 247
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 246
Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study 246
High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis 245
Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. 243
Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection 242
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial 240
Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver 240
The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance 240
MERTK rs4374383 polymorphism affects the severity of fibrosis in nonalcoholic fatty liver disease 238
Anti-hepatitis A virus seroprevalence and seroconversion in a cohort of patients with chronic viral hepatitis 238
Acute hepatitis C: in search of the optimal approach to cure. 237
Adefovir for lamivudine resistant HBV: More than meets the eye. 237
Clinical trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. 236
Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems 235
Cost-Effectiveness of Boceprevir or Telaprevir for Untreated Patients with Genotype 1 Chronic Hepatitis C 235
Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation 233
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 230
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. 229
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 229
Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients 228
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D. 228
Retinol-binding protein 4 (RBP4) : a new marker of G1 HCV-induced steatosis 227
Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. 227
Association of vitamin D serum levels and its common genetic determinants with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 227
Phylogenetic Analysis of isolates from new cases of HBV infection in Southern Italy. 226
IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. 226
Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis 225
Hepatitis B virus reactivation and alemtuzumab therapy 224
Coeliac disease: Oral ulcer prevalence, assessment of risk and association with gluten-free diet in children. 224
A patient with acute hepatitis C and possible IFN toxicity [2] 223
Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease 223
Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis 222
A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis 222
High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C 221
Serology in adults with celiac disease: limited accuracy in patients with mild histological lesions. 221
Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study 220
LIPIDOMICS OF FATTY LIVER IN NAFLD AND HCV INFECTION: LIVER SPHYNGOLIPIDS AND FATTY ACIDS 218
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C 218
STAGING OF FIBROSIS BY LIVER STIFFNESS MEASUREMENT IN THALASSEMICS WITH IRON OVERLOAD 216
Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. 216
Phylogenetic Reconstruction of HCV Genotype 1b Dissemination in a Small City Centre: The Camporeale Model 216
Halitosis: could it be more than mere bad breath? 215
TM6SF2 rs58542926 is not associated with steatosis and fibrosis in largecohort of patients with genotype 1 chronic hepatitis C 215
ATTUALI ORIENTAMENTI NELLA DIAGNOSTICA DELLA MALATTIA DI HIRSCHSPRUNG 215
Oral Mucosa of celiac disease patients produces anti-endomysial and anti-transglutaminase antibodes. Diagnostic usefulness of an in vitro culture system 214
Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. 214
PEG IFN alfa-2a vs. alfa-2b: And the winner is ...? 213
Liver disease in chelated transfusion-dependent thalassemics: the role of iron and chronic hepatitis C 213
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease 213
A woman with a long history of abdominal pain 212
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. 212
Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. 211
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 211
The aetiology of chronic hepatitis in Italy: results from a multicentre national study 210
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 210
Totale 25.305
Salva come PNG Salva come JPEG
Categoria #
all - tutte 271.874
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 271.874
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021656 0 0 0 0 0 0 0 0 0 0 0 656
2021/20225.471 273 1.147 159 148 154 230 279 410 686 637 383 965
2022/20236.755 759 1.533 114 648 701 1.047 402 457 683 48 254 109
2023/20242.362 139 416 162 195 196 514 231 138 42 54 18 257
2024/20257.000 197 424 422 734 192 235 426 467 560 881 889 1.573
2025/202626.818 1.523 726 1.370 1.986 2.511 4.037 3.756 2.810 2.604 3.594 1.317 584
Totale 77.950